$FTH News

BTIG Reiterates Buy on Faeth Therapeutics, Maintains $55 Price Target

Faeth Presents Updated Preclinical Data at ESMO, including First-Ever Head-to-Head Characterization of PIKTOR against Gedatolisib

Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Faeth to Present Preclinical Data on PIKTOR in HR+/HER2- Breast Cancer Models at ESMO 2026

William Blair Initiates Coverage On Faeth Therapeutics with Outperform Rating

Sensei Biotherapeutics Highlights PIKTOR Strategy Ahead of Endometrial Trial Readout

Faeth Therapeutics Appoints Karen Vousden, Ph.D., to Board of Directors

Guggenheim Initiates Coverage On Faeth Therapeutics with Buy Rating, Announces Price Target of $70

LUCID CAPITAL MARKETS Initiates Coverage On Faeth Therapeutics with Buy Rating, Announces Price Target of $59

TD Cowen Initiates Coverage On Faeth Therapeutics with Buy Rating

Faeth Therapeutics to Host Virtual KOL Event on Multi-Nodal Inhibition for the Treatment of Endometrial Cancer on October 6, 2026

What Makes Faeth Therapeutics, Inc. (FTH) a Strong Momentum Stock: Buy Now?

Faeth Therapeutics to Participate in Upcoming September Investor Conferences

Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wall Street Analysts Predict a 72.22% Upside in Faeth Therapeutics, Inc. (FTH): Here's What You Should Know

Needham Initiates Coverage On Faeth Therapeutics with Buy Rating, Announces Price Target of $56

Faeth Therapeutics Announces FDA Grant of Fast Track Designation for PIKTOR Plus Paclitaxel in Biomarker-Selected Advanced Endometrial Cancer

Faeth Therapeutics Says FDA Grants Fast Track Designation To Combination Of Sapanisertib And Serabelisib With Paclitaxel For Treatment Of Patients With Endometrial Cancer

Faeth Therapeutics Strengthens Executive Team with Senior Leadership Appointments

Faeth Therapeutics: PI3K Pathway Inhibitor With Key Data Catalyst In Play Intrigues